menu ☰
menu ˟

Clinical study of ARC-AAT for LD associated with AATD begins

07 Sep 2016
Arrowhead Pharmaceuticals Inc. announced it began a phase 2 clinical study of its ARC-AAT, an investigational RNA interference-based drug for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. According to the company, ARC...

Click here to view the full article which appeared in

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.